Alveolar rhabdomyosarcoma has superior response rates to vinorelbine compared to embryonal rhabdomyosarcoma in patients with relapsed/refractory disease: A meta-analysis.

ABSTRACT:

Background

Patients with alveolar rhabdomyosarcoma (ARMS) have inferior outcomes compared to patients with embryonal rhabdomyosarcoma (ERMS) and more effective chemotherapy options are needed for these patients. Vinorelbine is a semisynthetic vinca alkaloid that has clinical activity in relapsed rhabdomyosarcoma (RMS) when used alone or in combination with cyclophosphamide.

Aims

The goal of our study was to evaluate whether RMS histology subtype influences response rate to vinorelbine alone or in combination.

Materials & methods

Five Phase 2 trials that enrolled RMS patients were included in the meta-analysis. Two studies evaluated vinorelbine alone, two studies evaluated vinorelbine in combination with low dose oral cyclophosphamide, and one study evaluated vinorelbi

SUBMITTER: Allen-Rhoades W 

PROVIDER: S-EPMC10225185 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature